Difference between revisions of "Kaposi sarcoma - null regimens"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "|Years of enrollment" to "|Dates of enrollment") |
m |
||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | The purpose of this page is to provide references to "null therapy" such as placebo and observation. | + | <span id="BackToTop"></span> |
| + | <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px"> | ||
| + | [[#top|Back to Top]] | ||
| + | </div> | ||
| + | The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the [[Kaposi sarcoma|main KS page]] for regimens that include active anticancer treatment. | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
| Line 5: | Line 9: | ||
=All lines of therapy= | =All lines of therapy= | ||
==Placebo== | ==Placebo== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen=== | ===Regimen=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
| Line 13: | Line 17: | ||
!style="width: 20%"|Comparator | !style="width: 20%"|Comparator | ||
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
| + | |- | ||
| + | |[https://doi.org/10.1097/00126334-199911010-00004 Walmsley et al. 1999] | ||
| + | |1996-04 to 1997-07 | ||
| + | | style="background-color:#1a9851" |Phase 3 (C) | ||
| + | |[[Kaposi_sarcoma#Alitretinoin_monotherapy|Alitretinoin]] | ||
| + | | style="background-color:#d73027" |Inferior ORR | ||
| + | |- | ||
| + | |[https://doi.org/10.2165/00128071-200102020-00004 Bodsworth et al. 2001] | ||
| + | |NR | ||
| + | | style="background-color:#1a9851" |Phase 3 (C) | ||
| + | |[[Kaposi_sarcoma#Alitretinoin_monotherapy|Alitretinoin]] | ||
| + | | style="background-color:#d73027" |Inferior ORR | ||
|- | |- | ||
|[https://doi.org/10.1200/JCO.2005.11.043 Noy et al. 2005 (AMC 013)] | |[https://doi.org/10.1200/JCO.2005.11.043 Noy et al. 2005 (AMC 013)] | ||
|1998-2001 | |1998-2001 | ||
| style="background-color:#1a9851" |Phase 3 (C) | | style="background-color:#1a9851" |Phase 3 (C) | ||
| − | |[[# | + | |[[#IM-862_monotherapy_999|IM-862]] |
| style="background-color:#91cf60" |Seems to have superior TTP | | style="background-color:#91cf60" |Seems to have superior TTP | ||
|- | |- | ||
|} | |} | ||
''No active antineoplastic treatment.'' | ''No active antineoplastic treatment.'' | ||
| + | </div> | ||
===References=== | ===References=== | ||
| − | + | #Walmsley S, Northfelt DW, Melosky B, Conant M, Friedman-Kien AE, Wagner B; Panretin Gel North American Study Group. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. J Acquir Immune Defic Syndr. 1999 Nov 1;22(3):235-46. [https://doi.org/10.1097/00126334-199911010-00004 link to original article] [https://pubmed.ncbi.nlm.nih.gov/10770343/ PubMed] | |
| − | #'''AMC 013:''' Noy A, Scadden DT, Lee J, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S, Gill P; AIDS Malignancy Consortium. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol. 2005 Feb 10;23(5):990-8. Epub 2004 Dec 14. [https://doi.org/10.1200/JCO.2005.11.043 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15598977 PubMed] | + | #Bodsworth NJ, Bloch M, Bower M, Donnell D, Yocum R; International Panretin Gel KS Study Group. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel in cutaneous AIDS-related Kaposi's sarcoma. Am J Clin Dermatol. 2001;2(2):77-87. [https://doi.org/10.2165/00128071-200102020-00004 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11705307/ PubMed] |
| + | #'''AMC 013:''' Noy A, Scadden DT, Lee J, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S, Gill P; AIDS Malignancy Consortium. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol. 2005 Feb 10;23(5):990-8. Epub 2004 Dec 14. [https://doi.org/10.1200/JCO.2005.11.043 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15598977/ PubMed] | ||
[[Category:Kaposi sarcoma regimens]] | [[Category:Kaposi sarcoma regimens]] | ||
Latest revision as of 11:59, 6 March 2024
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main KS page for regimens that include active anticancer treatment.
All lines of therapy
Placebo
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Walmsley et al. 1999 | 1996-04 to 1997-07 | Phase 3 (C) | Alitretinoin | Inferior ORR |
| Bodsworth et al. 2001 | NR | Phase 3 (C) | Alitretinoin | Inferior ORR |
| Noy et al. 2005 (AMC 013) | 1998-2001 | Phase 3 (C) | IM-862 | Seems to have superior TTP |
No active antineoplastic treatment.
References
- Walmsley S, Northfelt DW, Melosky B, Conant M, Friedman-Kien AE, Wagner B; Panretin Gel North American Study Group. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. J Acquir Immune Defic Syndr. 1999 Nov 1;22(3):235-46. link to original article PubMed
- Bodsworth NJ, Bloch M, Bower M, Donnell D, Yocum R; International Panretin Gel KS Study Group. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel in cutaneous AIDS-related Kaposi's sarcoma. Am J Clin Dermatol. 2001;2(2):77-87. link to original article PubMed
- AMC 013: Noy A, Scadden DT, Lee J, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S, Gill P; AIDS Malignancy Consortium. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol. 2005 Feb 10;23(5):990-8. Epub 2004 Dec 14. link to original article PubMed